For its first fiscal quarter (ending March 31), Catalyst Biosciences Inc (NASDAQ: CBIO) has reported a -83% decline in E.P.S. from $0.53 a year ago to $0.09 in the current quarter.
Recent Price Action
On 5/9/24, Catalyst Biosciences Inc (NASDAQ: CBIO) stock declined by -2.9%, closing at $15.23. However, trading volume in this decline was below average at 73% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 9.9% during the last week.
Current PriceTarget Research Rating
CBIO is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Catalyst Biosciences is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment